Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 December 2024 | Story Leonie Bolleurs | Photo Supplied
Yolandi Schoeman
Dr Yolandi Schoeman is redefining the future of ecological restoration with innovative solutions for both Earth and space.

Dr Yolandi Schoeman, a Senior Lecturer in Ecological Engineering in the Centre for Mineral Biogeochemistry at the University of the Free State (UFS) and the Ecological Engineering Institute of Africa, was fascinated by the synergy between engineering and the natural sciences from a young age.
 
She said that the potential within ecological engineering to regenerate ecosystems at all scales, from the microscopic to vast landscapes, really drew her in. “This field offers solutions not only for daily sustainability challenges but also for the threats to planetary health and human well-being. However, when I was starting out, ecological engineering wasn't recognised as a formal career path in South Africa, and studying it in the United States wasn't feasible for me at the time. So, I explored various educational paths in civil engineering and natural sciences, aiming to merge these disciplines in my projects and research. My ultimate goal has been to establish and develop the field of ecological engineering both in South Africa and across Africa,” she explained. 

Conventional and extreme ecological engineering

Dr Schoeman’s work in ecological engineering spans two main areas: conventional and extreme ecological engineering. On the conventional side, she says she is focusing on projects like designing constructed wetlands to naturally treat water, implementing urban greening initiatives to cool cities and manage stormwater, and regenerating various habitats to strengthen biodiversity. In terms of extreme ecological engineering, she focuses on developing innovative solutions for ecosystems that have been severely impacted by disasters like industrial accidents or natural calamities. 

Additionally, she is leading efforts in astro-ecological engineering, applying these principles to rehabilitate severely damaged terrestrial environments while exploring their potential for extraterrestrial applications, advancing both sustainability and ecological restoration.

There are two moments in her journey that Dr Schoeman recalled helped shape her career. One was being invited to participate in the 2006 Brightest Young Minds initiative, hosted by the University of Stellenbosch. She said that it was the first platform where she could really develop and share her ideas and vision in ecological engineering. “I contributed to a publication titled Engineering Engineering, which focused on integrating nature into every facet of development and operations. That experience validated my vision of combining engineering and natural systems.”

The other experience came during her studies in Executive Leadership at the Skolkovo School of Management in Moscow. “I was tasked with leading a multidisciplinary, international team that had to create a sustainability strategy for a major international iron, steel and vanadium company. The project pushed me to defend sustainability solutions that would alter the way this industrial giant operated. It was a deeply challenging process that changed my perception of true sustainability and what it means to deliver solutions that are both impactful and make business sense. That moment forced me to step out of the comfort zone of conventional sustainability and reorient my path toward pursuing solutions that seemed almost impossible, but necessary.”

Advancing ecological engineering across Africa

Two of the most important research projects she has been involved in include advancing ecological engineering across Africa and restoring and managing ecosystems that are considered beyond conventional repair. The first project involved establishing an international institution that spearheads various innovative research areas, including exploring floating treatment wetlands, different types of constructed wetlands, and technologies for smarter ecosystem management in urban and rural contexts. “This comprehensive project has substantially elevated the global understanding and application of ecological engineering, addressing a spectrum of sustainability challenges,” she said.

In the second project she worked with a team that tackled severely degraded environments like post-mining landscapes, heavily polluted industrial sites, and areas where ecosystem functionality has been drastically compromised. She also aims to develop the projects further and to collaborate with agencies like NASA to design life-support systems for future space habitats. “These systems are not limited to space applications, but are also designed to address complex planetary health issues in extreme environments on Earth, such as war zones, nuclear disaster areas, and sites affected by climatic catastrophes,” she remarked.

Dr Schoeman is also responsible for the "Astroecological Engineering System" (AES). “This system uniquely integrates terrestrial ecological engineering principles with astro-ecological technologies to deal with some of the most challenging environmental restoration projects on Earth and potentially in future space habitats,” she stated, adding that AES is specifically designed for restoring heavily degraded or contaminated ecosystems – situations where traditional restoration methods are inadequate. 

Pushing the boundaries of what’s possible 

She believes AES is a versatile tool for addressing some of the most daunting environmental challenges we currently face. This passion for handling seemingly insurmountable problems is what drives her work. 

“These are the issues that often push the boundaries of what's possible in ecological engineering. Each project that seems 'impossible' provides an opportunity not just to solve a problem, but to innovate and create methods that can be applied globally. It's about turning what was once thought unachievable into tangible, impactful realities that improve our environment and our relationship with the natural world. I truly believe that humanity holds the pen that can rewrite our future.”

About the future, she says that over the next 15 years she would like to see extreme ecological engineering, supported by astro-ecological insights, evolve into a foundational strategy in global environmental management. This approach will be key in scenarios where traditional restoration methods are inadequate. “My goal is to integrate these advanced, resilient techniques into mainstream disaster response and urban planning processes worldwide, preparing ecosystems and communities to withstand and adapt to future ecological stresses,” she said.

She also envisions a future where the principles of extreme and astro-ecological engineering are routinely taught in academic institutions and incorporated into public policy. “By raising awareness and building expertise on a global scale, I aim to cultivate a new generation of engineers – those who are not only equipped to take on severe environmental crises on Earth but are also prepared for the ecological challenges we may face in space. This ambitious vision drives a shift towards more resilient and adaptive management of Earth's ecosystems, ensuring they thrive amidst the challenges of the 21st century.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept